Melphalan and its role in the management of patients with multiple myeloma

References

• Phekoo KJ, Schey SA, Richards MA, Bevan DH, Gillett D, Møller H. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in the United Kingdom. Br. J. Haematol.127, 299–304 (2004).
   PubMed Web of Science ®Google Scholar
• Wingo PA, Ries LA, Rosemberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973–1995: a report card for the U.S. Cancer82, 1197–2007 (1998).
   PubMed Web of Science ®Google Scholar
• Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase 5(2.0), IARC Press, Lyon, France (2004).
   Google Scholar
• Ries LA, Eisner MP, Kosary CL et al.SEER Cancer Statistics Review, 1975–2000. National Cancer Institute. National Cancer Institute, MD, USA (2003).
   Google Scholar
• Bergel F, Stock JA. Cytotoxic α amino acids and endopeptidase. Br. Emp. Cancer Comp. Annu.31, 6–21 (1953).
   Google Scholar
• Alberts DS, Chang SY, Chen H-SG et al. Oral melphalan kinetics. Clin. Pharmacol. Ther.26, 737–745 (1979).
   PubMed Web of Science ®Google Scholar
• Samuels BL, Bitran JD. High dose intravenous melphalan: a review. J. Clin. Oncol.13, 1786–1799 (1995).
   PubMed Web of Science ®Google Scholar
• Cornwell GG III, Pajak TF, McIntyre OR, Kochwa S, Dosik H. Influence of renal failure on myelosuppressive effects of melphalan: Cancer and Leukemia Group B experience. Cancer Treat. Rep.66, 475–481 (1982).
   PubMedGoogle Scholar
• Adair CG, Bridges JM, Desai ZR. Renal function in the elimination of oral melphalan in patients with cancer. Cancer Chemother. Pharmacol.22, 348–352 (1988).
   PubMed Web of Science ®Google Scholar
• Tranchand B, Ploin YD, Minuit MP et al. High-dose melphalan dosage adjustment: possibly of using a test-dose. Cancer Chemother. Pharmacol.23, 95–100 (1989).
   PubMed Web of Science ®Google Scholar
• Pinguet F, Martel P, Fabbro M et al. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic preogenitor-cell transplantation. Anticancer Res.17, 605–612 (1997).
   PubMed Web of Science ®Google Scholar
• Tricot G, Alberts DS, Johnson C et al. Safety of autotransplant with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin. Cancer Res.2, 947–952 (1996).
   PubMed Web of Science ®Google Scholar
• Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch. Intern. Med.150, 1693–1695 (1990).
   PubMed Web of Science ®Google Scholar
• Knudsen LM, Hippe E, Hjort M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma – a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur. J. Hematol.53, 207–212 (1994).
   PubMed Web of Science ®Google Scholar
• Winearls CG. Acute myeloma kidney. Kidney Int.48, 1347–1361 (1995).
   PubMed Web of Science ®Google Scholar
• Ballester OF, Tummala R, Janseen WE et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant.20, 653–656 (1997).
   PubMed Web of Science ®Google Scholar
• Rebibou JM, Caillot D, Casasnovas RO et al. Peripheral blood stem cell transplantation in multiple myeloma patients with end-stage renal failure. Bone Marrow Transplant.20, 63–65 (1997).
   PubMed Web of Science ®Google Scholar
• Tosi P, Zamagni E, Ronconi S et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia14, 1310–1313 (2000).
   PubMed Web of Science ®Google Scholar
• Bird JM, Fuge R, Sirohi B et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study. Br. J. Haematol.134, 385–390 (2006).
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Lahuerta JJ, Garcia-Sanz R et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol. J.1, 28–36 (2000).
   PubMedGoogle Scholar
• Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br. J. Haematol.12, 651–654 (2001).
   Google Scholar
• Carlson K. Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant.35, 985–990 (2005).
   PubMed Web of Science ®Google Scholar
• Barosi G, Boccadoro M, Cavo M et al. Management of multiple myeloma and related disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica89, 717–741 (2004).
   PubMed Web of Science ®Google Scholar
• Smith A, Wisloff F, Samson D; UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br. J. Haematol.132, 410–451 (2006).
   PubMed Web of Science ®Google Scholar
• Alexanian R, Haut A, Khan AU et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. J. Am. Med. Assoc.208, 1680–1685 (1969).
   PubMed Web of Science ®Google Scholar
• Medical research Council’s Working Party on Leukaemia in Adults. Treatment comparisons in the third MRC myelomatosis trial. Br. J. Cancer.42, 823–830 (1980).
   PubMed Web of Science ®Google Scholar
• Myeloma Trialists’ Collaborative Group. Combination Chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J. Clin. Oncol.12, 3832–3842 (1998).
   Google Scholar
• Hernandez JM, Garcia-Sanz R, Golvano E et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br. J. Haematol.127, 159–164 (2004).
   PubMed Web of Science ®Google Scholar
• Facon T, Mary JY, Pegourie B et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood107, 1292–1298 (2006).
   PubMed Web of Science ®Google Scholar
• McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet2, 822–824 (1983).
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Milpied N, Laporte JP et al. Double intensive therapy in high risk multiple myeloma. Blood79, 2827–2833 (1992).
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Meuwissen OJ, Verdonck LF, Dekker AW. High risk multiple myeloma treated with high-dose melphalan. J. Clin. Oncol.10, 47–51 (1992).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Paz-Ares L, Gore ME et al. High-dose melphalan for multiple myeloma: long term follow-up data. J. Clin. Oncol.12, 759–753 (1992).
   Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med.335, 91–97 (1996).
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood89, 789–793 (1997).
   PubMed Web of Science ®Google Scholar
• Lenhoff S, Hjort M, Turesson I et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood95, 7–11 (2000).
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med.348, 1875–1883 (2003).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Petrucci MT et al. Intermediate-dose melphalan improve survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood104, 3052–3057 (2004).
   PubMed Web of Science ®Google Scholar
• Fermand JP, Katsahian S, Divine M et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J. Clin. Oncol.23, 9227–9233 (2005).
   PubMed Web of Science ®Google Scholar
• Blade J, Esteve J, Rives S et al. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant.26, 845–849 (2000).
   PubMed Web of Science ®Google Scholar
• Barlogie B, Kyle RA, Anderson KC et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of Phase III US Intergroup Trial S9321. J. Clin. Oncol.24, 929–936 (2006).
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem cell transplantation from multiple myeloma. N. Engl. J. Med.349, 2495–2502 (2003).
   PubMed Web of Science ®Google Scholar
• Moreau P, Facon T, Attal M et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood99, 731–735 (2002).
   PubMed Web of Science ®Google Scholar
• Haas PS, Kuehnemund A, Bauchmuller K, Engelhardt M. Efficacy of diverse high dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single center analysis over a 12 year period. Ann. Hematol.85,191–193 (2006).
   PubMed Web of Science ®Google Scholar
• Desikan KR, Tricot G, Dhodapkar M et al. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant.25, 483–487 (2000).
   PubMed Web of Science ®Google Scholar
• Badros A, Barlogie B, Siegel E et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br. J. Haematol.114, 600–607 (2001).
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Anaissie E et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N. Engl. J. Med.354, 1021–1030 (2006).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Bertola A et al. Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2). Leukemia18, 133–138 (2004).
   PubMed Web of Science ®Google Scholar
• Facon T, Mary J, Harousseau J et al. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J. Clin. Oncol.24, S18 (2006).
   Google Scholar
• Palumbo A, Bertola A, Musto P et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer104, 1428–1433 (2005).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Terpos E et al. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica91, 252–254 (2006).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet367, 825–831 (2006).
   PubMed Web of Science ®Google Scholar
• Srkalovic G, Elson P, Hussein MA. Use of melphalan, thalidomide and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med. Oncol.194, 219–226 (2002)
   Google Scholar
• Palumbo A, Avonto I, Bruno B et al. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur. J. Haematol.76, 273–277 (2006).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Falco P, Falcone A et al. Oral Revlimid® plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: results of a multicenter Phase I/II study. Blood108, (2006) (Abstract 800).
   Google Scholar
• Mateos MV, Hernandez JM, Hernandez MT et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood108, 2165–2172 (2006).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Ambrosini MT, Benevolo G et al. Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma. Blood109, 2767–2772 (2006).
   Web of Science ®Google Scholar
• Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am. J. Hematol.33, 86–89 (1990).
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood93, 55–65 (1999).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol.20, 4319–4323 (2002).
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Tosi P et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica89, 826–831 (2004).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol.24, 431–436 (2006).
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Tosi P et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood106, 35–39 (2005).
   PubMed Web of Science ®Google Scholar
• Macro M, Divine M, Uzunhan Y et al. Dexamethasone + thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial. Blood108, 57 (2006).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood106, 4050–4053 (2005).
   PubMed Web of Science ®Google Scholar
• Lacy M, Gertz M, Dispenzieri A et al. Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival. Blood108, (2006) (Abstract 798).
   PubMedGoogle Scholar
• Jagannath S, Durie BG, Wolf J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br. J. Haematol.129, 776–783 (2005).
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Leleu X et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM Phase II study. Haematologica91, 1498–505 (2006).
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Marit J, Caillot D et al. Velcade/dexamethasone (Vel/Dex) versus VAD as induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): an interim analysis of the IFM 2005–01 randomized multicenter Phase III trial. Blood108, (2006) (Abstract 56).
   Google Scholar
• Oakervee HE, Popat R, Curry N et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Haematol.129, 755–762 (2005)
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dispenzieri A. Evaluation and monitoring of response to therapy in multiple myeloma. Haematologica90, 1305–1308 (2005).
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Leyvraz S et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood108, 3289–3294 (2006).
   PubMed Web of Science ®Google Scholar
• Roussel M, Danho C, Huynh A et al. Bortezomib and high dose melphalan: a new conditioning regimen before autologous stem cell transplantation for multiple myeloma. Haematologica,91, S1 (2006) (Abstract 233).
   Web of Science ®Google Scholar
• Palumbo A, Avonto I, Bruno B et al. Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma. Clin. Lymphoma Myeloma6, 475–477 (2006).
   PubMedGoogle Scholar
• Lonial S, Kaufman J, Langston AA et al. A randomized Phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma: the effect of sequence of administration. Biol. Blood Marrow Transplant.13(2 Suppl.) 56 (2007).
   PubMedGoogle Scholar
• Hideshima T, Chauhan D, Richardson P, Anderson KC. Identification and validation of novel therapeutic targets for multiple myeloma. J. Clin. Oncol.23, 6345–6350 (2005).
   PubMed Web of Science ®Google Scholar
• Podar K, Tonon G, Sattler M et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc. Natl Acad. Sci. USA103, 19478–19483 (2006).
   PubMed Web of Science ®Google Scholar
• Greco C, D’Agnano I, Vitelli G et al. c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB. Int. J. Immunopathol. Pharmacol.19, 67–79 (2006).
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 2505–2512 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Podar K, Raab MS, Zhang J et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood109, 1669–1677 (2007).
   PubMed Web of Science ®Google Scholar
• Carducci MA, Musib L, Kies MS et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase Cβ inhibitor, in patients with advanced cancer. J. Clin. Oncol.24, 4092–4099 (2006).
   PubMed Web of Science ®Google Scholar
• Drach J, Ackermann J, Fritz E et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood92, 802–809 (1998).
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Treon SP, Mitsiades N et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood98, 795–804 (2001).
   PubMed Web of Science ®Google Scholar
• Rowinsky EK. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J. Clin. Oncol.23, 9394–9407 (2005).
   PubMed Web of Science ®Google Scholar
• Richardson P, Lonial S, Krishnan A et al. A multicenter Phase I clinical trial of tanespimycin (KOS-953) + bortezomib (BZ): encouraging activity and manageable toxicity in heavily pre-treated patients with relapsed refractory multiple myeloma (MM). Blood108, 406 (2006).
   Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades NS, McMullan CJ et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood107, 1092–1100 (2006).
   PubMed Web of Science ®Google Scholar